<DOC>
	<DOCNO>NCT00800787</DOCNO>
	<brief_summary>A phase 3 , multicenter , open label study assess safety efficacy Nabi-HB , administer subcutaneously patient Hepatitis B Virus Associated Liver Disease underwent liver transplantation .</brief_summary>
	<brief_title>Nabi-HB Administered Subcutaneously Patients With Hepatitis B Virus Post Liver Transplantation</brief_title>
	<detailed_description>This phase 3 prospective , single arm open label study conduct approximately 4 study sit locate th e USA . Approximately 25 HBV DNA negative patient underwent liver transplant least one year prior , due chronic hepatitis B infection bwe eligible study participation . The study consist total 16 study visit duration participation 20 week patient . Patients convert intravenous standard HBIG Nabi-HB subcutaneous administration accord individual schedule dose interval .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>Male female patient 18 year old old visit one . If female try conserve , lactating , negative serum pregnancy test use acceptable method contraception least one year postmenopausal surgically sterile . Able provide write informed consent . First time liver transplant recipient . Primary , single organ recipient ( decease donor &lt; 65 year old ) . receive regular longterm HBIG prophylaxis stabilize HBIG dosage administration interval . Have negative quantifiable HBVDNA HBsAg result prior dose visit 2 . Following last IV administration HBIG , baseline serum antiHBs level &gt; 150 IU/ML prior dose visit 2 . Exclusion Criteria Positive HCV HIV test result . Unexplained elevate liver function test . Serum creatinine level &gt; 2.0 time upper limit normal . life expectancy &lt; 6 month . liver transplantation ongoing acute rejection episode . Donor liver hepatitis Bor C positive donor . Underwent liver transplant &lt; 12 month prior visit 1 . Know history cancer , suspect cancer , cancer therapy within 12 month . History autoimmune disease . History/current evidence coagulation disorder , severe cardiac disease , unhealed gastric duodenal ulcer , significant disease . Evidence unresolved infection unresolved opportunistic infection require treatment . Known immunoglobulin A deficiency . History use immunosupressive immunomodulatory drug within 3 month prior visit 1 . ( except low dose glucocorticoid therapy , &lt; 10 mg prednisone equivalent per day . ) receive investigational drug 30 day prior visit 1. use plasma preparation immunoglobulins study . Know intolerance protein human origin , immunoglobulin , comparable product . Evidence alcohol and/or drug abuse within 6 month visit 2 inability/unwillingness abstain alcohol duration study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Chronic hepatitis B liver disease</keyword>
</DOC>